| Health care–associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections ND Friedman, KS Kaye, JE Stout, SA McGarry, SL Trivette, JP Briggs, ... Annals of internal medicine 137 (10), 791-797, 2002 | 2019 | 2002 |
| Strategies to prevent surgical site infections in acute care hospitals: 2014 update DJ Anderson, K Podgorny, SI Berríos-Torres, DW Bratzler, EP Dellinger, ... Infection Control & Hospital Epidemiology 35 (S2), S66-S88, 2014 | 1605 | 2014 |
| The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges SE Cosgrove, Y Qi, KS Kaye, S Harbarth, AW Karchmer, Y Carmeli Infection Control & Hospital Epidemiology 26 (2), 166-174, 2005 | 1284 | 2005 |
| Adverse Clinical and Economic Outcomes Attributable to Methicillin Resistance among Patients with Staphylococcus aureus Surgical Site Infection JJ Engemann, Y Carmeli, SE Cosgrove, VG Fowler, MZ Bronstein, ... Clinical infectious diseases 36 (5), 592-598, 2003 | 1268 | 2003 |
| International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP), European society of clinical … BT Tsuji, JM Pogue, AP Zavascki, M Paul, GL Daikos, A Forrest, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39 (1 …, 2019 | 859 | 2019 |
| Strategies to prevent surgical site infections in acute care hospitals DJ Anderson, KS Kaye, D Classen, KM Arias, K Podgorny, H Burstin, ... Infection Control & Hospital Epidemiology 29 (S1), S51-S61, 2008 | 681 | 2008 |
| Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae D Van Duin, JJ Lok, M Earley, E Cober, SS Richter, F Perez, RA Salata, ... Clinical Infectious Diseases 66 (2), 163-171, 2018 | 654 | 2018 |
| Diabetes and risk of surgical site infection: a systematic review and meta-analysis ET Martin, KS Kaye, C Knott, H Nguyen, M Santarossa, R Evans, ... Infection Control & Hospital Epidemiology 37 (1), 88-99, 2016 | 637 | 2016 |
| Clinical and Economic Impact of Bacteremia with Extended- Spectrum-β-Lactamase-Producing Enterobacteriaceae MJ Schwaber, S Navon-Venezia, KS Kaye, R Ben-Ami, D Schwartz, ... Antimicrobial agents and chemotherapy 50 (4), 1257-1262, 2006 | 603 | 2006 |
| Strategies to prevent central line–associated bloodstream infections in acute care hospitals J Marschall, LA Mermel, D Classen, KM Arias, K Podgorny, DJ Anderson, ... Infection Control & Hospital Epidemiology 29 (S1), S22-S30, 2008 | 602 | 2008 |
| Strategies to prevent ventilator-associated pneumonia in acute care hospitals SE Coffin, M Klompas, D Classen, KM Arias, K Podgorny, DJ Anderson, ... Infection Control & Hospital Epidemiology 29 (S1), S31-S40, 2008 | 541 | 2008 |
| Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections HJ Morrill, JM Pogue, KS Kaye, KL LaPlante Open forum infectious diseases 2 (2), ofv050, 2015 | 540 | 2015 |
| Strategies to prevent catheter-associated urinary tract infections in acute care hospitals E Lo, L Nicolle, D Classen, KM Arias, K Podgorny, DJ Anderson, H Burstin, ... Infection Control & Hospital Epidemiology 29 (S1), S41-S50, 2008 | 514 | 2008 |
| Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes D Van Duin, KS Kaye, EA Neuner, RA Bonomo Diagnostic microbiology and infectious disease 75 (2), 115-120, 2013 | 496 | 2013 |
| Infections caused by resistant gram‐negative bacteria: epidemiology and management KS Kaye, JM Pogue Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 35 (10 …, 2015 | 487 | 2015 |
| Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system JM Pogue, J Lee, D Marchaim, V Yee, JJ Zhao, T Chopra, P Lephart, ... Clinical infectious diseases 53 (9), 879-884, 2011 | 438 | 2011 |
| Effect and safety of meropenem–vaborbactam versus best-available therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial RG Wunderink, EJ Giamarellos-Bourboulis, G Rahav, AJ Mathers, ... Infectious diseases and therapy 7, 439-455, 2018 | 431 | 2018 |
| Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species SE Cosgrove, KS Kaye, GM Eliopoulous, Y Carmeli Archives of internal medicine 162 (2), 185-190, 2002 | 421 | 2002 |
| Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus RL Nation, J Li, O Cars, W Couet, MN Dudley, KS Kaye, JW Mouton, ... The Lancet infectious diseases 15 (2), 225-234, 2015 | 408 | 2015 |
| Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non … RG Wunderink, Y Matsunaga, M Ariyasu, P Clevenbergh, R Echols, ... The Lancet Infectious Diseases 21 (2), 213-225, 2021 | 398 | 2021 |
